Efficacy and safety of the pulsed infusions of levosimendan in outpatients with advanced heart failure (LevoRep) study: a multicentre randomized trial

The aim of this study was to determine whether intermittent ambulatory treatment with levosimendan would improve functional capacity, quality of life, and event‐free survival in patients with advanced heart failure.

[1]  M. Drazner,et al.  2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.

[2]  B. Massie,et al.  Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure. , 2013, JACC. Heart failure.

[3]  Biykem Bozkurt,et al.  2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. , 2013, Circulation.

[4]  G. Parati,et al.  Intermittent Levosimendan Infusions in Advanced Heart Failure: Favourable Effects on Left Ventricular Function, Neurohormonal Balance, and One-Year Survival , 2012, Journal of cardiovascular pharmacology.

[5]  M. Anastasiou-Nana,et al.  Comparison of three different regimens of intermittent inotrope infusions for end stage heart failure. , 2012, International journal of cardiology.

[6]  A. Parkhomenko,et al.  Levosimendan: molecular mechanisms and clinical implications: consensus of experts on the mechanisms of action of levosimendan. , 2012, International journal of cardiology.

[7]  G. Biondi-Zoccai,et al.  Effects of levosimendan on mortality and hospitalization. A meta-analysis of randomized controlled studies* , 2012, Critical care medicine.

[8]  L. A. Bonet,et al.  ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 , 2010, European journal of heart failure.

[9]  L. A. Bonet,et al.  ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 , 2012, Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir.

[10]  Clyde B. Schechter,et al.  Changing Characteristics and Mode of Death Associated With Chronic Heart Failure Caused by Left Ventricular Systolic Dysfunction: A Study Across Therapeutic Eras , 2011, Circulation. Heart failure.

[11]  H. Ulmer,et al.  Rationale and design of the multicentre randomized trial investigating the efficacy and safety of pulsed infusions of levosimendan in outpatients with advanced heart failure (LevoRep study) , 2010, European journal of heart failure.

[12]  J. McMurray,et al.  Clinical practice. Systolic heart failure. , 2010, The New England journal of medicine.

[13]  P. Ponikowski,et al.  Palliative care in heart failure: a position statement from the palliative care workshop of the Heart Failure Association of the European Society of Cardiology , 2009, European journal of heart failure.

[14]  G. Filippatos,et al.  Novel biologic mechanisms of levosimendan and its effect on the failing heart , 2008, Expert opinion on investigational drugs.

[15]  C. Yancy,et al.  Safety and Efficacy of Outpatient Nesiritide in Patients With Advanced Heart FailureCLINICAL PERSPECTIVE , 2008 .

[16]  C. Yancy,et al.  Safety and efficacy of outpatient nesiritide in patients with advanced heart failure: results of the Second Follow-Up Serial Infusions of Nesiritide (FUSION II) trial. , 2008, Circulation. Heart failure.

[17]  D. Drossman,et al.  Components of placebo effect: randomised controlled trial in patients with irritable bowel syndrome , 2008, BMJ : British Medical Journal.

[18]  M. Costanzo,et al.  Characteristics of "Stage D" heart failure: insights from the Acute Decompensated Heart Failure National Registry Longitudinal Module (ADHERE LM). , 2008, American heart journal.

[19]  G. Filippatos,et al.  Novel biologic mechanisms of levosimendan and its effect on the failing heart. , 2008, Expert opinion on investigational drugs.

[20]  A. Bayés‐Genís,et al.  Serial NT-proBNP monitoring and outcomes in outpatients with decompensation of heart failure. , 2007, International journal of cardiology.

[21]  S. Mavrogeni,et al.  A 6-month follow-up of intermittent levosimendan administration effect on systolic function, specific activity questionnaire, and arrhythmia in advanced heart failure. , 2007, Journal of cardiac failure.

[22]  A. Cohen-Solal,et al.  Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. , 2007, JAMA.

[23]  J. Kors,et al.  Prevalence and Prognostic Significance of Heart Failure Stages: Application of the American College of Cardiology/American Heart Association Heart Failure Staging Criteria in the Community , 2007, Circulation.

[24]  D. Moertl,et al.  Levosimendan and prostaglandin E1 for uptitration of beta‐blockade in patients with refractory, advanced chronic heart failure , 2007, European journal of heart failure.

[25]  G. Filippatos,et al.  Effects of serial levosimendan infusions on left ventricular performance and plasma biomarkers of myocardial injury and neurohormonal and immune activation in patients with advanced heart failure , 2006, Heart.

[26]  H. Krumholz,et al.  Monitoring clinical changes in patients with heart failure: a comparison of methods. , 2005, American heart journal.

[27]  M. Anastasiou-Nana,et al.  Efficacy and safety of intermittent, long-term, concomitant dobutamine and levosimendan infusions in severe heart failure refractory to dobutamine alone. , 2005, The American journal of cardiology.

[28]  Nick Freemantle,et al.  The impact of chronic heart failure on health‐related quality of life data acquired in the baseline phase of the CARE‐HF study , 2005, European journal of heart failure.

[29]  L. Stevenson,et al.  Clinical use of inotropic therapy for heart failure: looking backward or forward? Part II: chronic inotropic therapy. , 2003, Circulation.

[30]  M. Nieminen,et al.  Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN). , 2002, European heart journal.

[31]  N. Freemantle,et al.  The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure—a meta‐regression analysis , 2002, European journal of heart failure.

[32]  J. Cleland,et al.  Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial , 2002, The Lancet.

[33]  Stefan Sack,et al.  Long-term clinical effect of hemodynamically optimized cardiac resynchronization therapy in patients with heart failure and ventricular conduction delay. , 2002, Journal of the American College of Cardiology.

[34]  D. Delurgio,et al.  Cardiac resynchronization in chronic heart failure. , 2002, The New England journal of medicine.

[35]  W. Herzog,et al.  Health related quality of life in patients with congestive heart failure: comparison with other chronic diseases and relation to functional variables , 2002, Heart.

[36]  J. Papp,et al.  STEERING COMMITTEE AND INVESTIGATORS OF THE LEVOSIMENDAN INFUSION VERSUS DOBUTAMINE (LIDO) STUDY. EFFICACY AND SAFETY OF INTRAVENOUS LEVOSIMENDAN COMPARED WITH DOBUTAMINE IN SEVERE LOWOUTPUT HEART FAILURE (THE LIDO STUDY): A RANDOMISED DOUBLEBLIND TRIAL , 2002 .

[37]  J. Daubert,et al.  Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. , 2001, The New England journal of medicine.

[38]  Arma,et al.  EFFECTS OF MULTISITE BIVENTRICULAR PACING IN PATIENTS WITH HEART FAILURE AND INTRAVENTRICULAR CONDUCTION DELAY , 2001 .

[39]  M. Nieminen,et al.  Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. , 2000, Journal of the American College of Cardiology.

[40]  S. Gottlieb,et al.  Acute Hemodynamic and Clinical Effects of Levosimendan in Patients With Severe Heart Failure , 2000, Circulation.

[41]  J. Young,et al.  Outpatient parenteral inotropic therapy for advanced heart failure. , 2000, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[42]  Rapezzi,et al.  The case against outpatient parenteral inotropic therapy for advanced heart failure , 2000, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[43]  N. Kalkkinen,et al.  Binding of a new Ca2+ sensitizer, levosimendan, to recombinant human cardiac troponin C. A molecular modelling, fluorescence probe, and proton nuclear magnetic resonance study. , 1994, The Journal of biological chemistry.